Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 5/20 | 0.45 |
| ▸ | PPARG | P37231 | 3/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | ESR1 | P03372 | 3/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.42 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.42 |
| ▸ | HTR3B | O95264 | 1/20 | 0.42 |
| ▸ | HTR3A | P46098 | 1/20 | 0.42 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.42 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4051251 | 0.86 | ACHE (0.44) | ACHEMAOBESR1ESR2HRH3 | |
| SCHEMBL4048452 | 0.84 | MEN1 (0.43) | PPARGMAOB | |
| SCHEMBL4044883 | 0.83 | CACNA1B (0.43) | MAOB | |
| SCHEMBL4046992 | 0.82 | ALDH1A1 (0.47) | PPARGMAOB | |
| SCHEMBL4043815 | 0.82 | PPARG (0.49) | PPARGMAOBESR1 | |
| SCHEMBL4045388 | 0.78 | ALDH1A1 (0.49) | — | |
| SCHEMBL4049133 | 0.78 | CACNA1B (0.44) | ACHEMAOB | |
| SCHEMBL5422453 | 0.77 | ALDH1A1 (0.50) | — | |
| SCHEMBL4045889 | 0.77 | CACNA1B (0.43) | ACHEPPARGMAOBESR1 | |
| SCHEMBL5435148 | 0.76 | KDM4E (0.44) | ACHEPPARGMAOBESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1603921-B1 | THIADIBENZOAZULENE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES | GLAXOSMITHKLINE ZAGREB (HR) | 2009-06-17 | — | — | EP | claimed |
| US-20060069149-A1 | Thiadibenzoazulene derivatives for the treatment of inflammatory diseases | PLIVA-ISTRAZIVACKI INSTITUT D.O.O. (HR) | 2006-03-30 | — | — | US | claimed |
| EP-1603921-B1 | THIADIBENZOAZULENE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES | GLAXOSMITHKLINE ZAGREB (HR) | 2009-06-17 | — | — | EP | disclosed |
| US-20060069149-A1 | Thiadibenzoazulene derivatives for the treatment of inflammatory diseases | PLIVA-ISTRAZIVACKI INSTITUT D.O.O. (HR) | 2006-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069149-A1 | Thiadibenzoazulene derivatives for the treatment of inflammatory diseases | IL1B, IL1A, TNF | ACHE 1757/4885PPARG 296/4885MAOB 1459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.